All In Biotech

Drug Trial Radar · NCT07459283

The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
Collaborators
Affiliated Hospital of Jiangnan University
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.

Conditions

  • Maligant Solid Tumor
  • Head & Neck Cancer
  • Thyroid Cancer
  • Lung Cancer - Non Small Cell Squamous
  • Breast Cancer
  • Sarcoma

Interventions

  • INN805Drug

    The drug was administered once every 6 weeks. It was expected that the drug would be administered for 1 to 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine dose-limiting toxicity (DLT)Time frame: 42 days after first dose
  2. Frequency of adverse events (AEs) and SAEsTime frame: Approximately 12 months
  3. Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.